» Authors » Keith Johnson

Keith Johnson

Explore the profile of Keith Johnson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 102
Citations 3689
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Coughlan G, Rubinstein Z, Klinger H, Lopez K, Hsieh S, Boyle R, et al.
Sci Adv . 2025 Mar; 11(10):eadt1288. PMID: 40043125
Elucidating the downstream impact of exogenous hormones on the aging brain will have far-reaching consequences for understanding why Alzheimer's disease (AD) predominates in women almost twofold over men. We tested...
2.
Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G, et al.
Alzheimers Dement . 2025 Mar; 21(3):e14528. PMID: 40042435
Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is...
3.
Tiss A, Chemli Y, Guehl N, Marin T, Johnson K, El Fakhri G, et al.
IEEE Trans Radiat Plasma Med Sci . 2024 Nov; 8(8):950-958. PMID: 39507127
Motion is unavoidable in dynamic [F]-MK6240 Positron Emission Tomography (PET) imaging, especially in Alzheimer's disease (AD) research requiring long scan duration. To understand how motion correction affects quantitative analysis, we...
4.
Nho K, Risacher S, Apostolova L, Bice P, Brosch J, Deardorff R, et al.
Nat Commun . 2024 Sep; 15(1):8251. PMID: 39304655
Determining the genetic architecture of Alzheimer's disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron...
5.
Quiroz Y, Aguillon D, Aguirre-Acevedo D, Vasquez D, Zuluaga Y, Baena A, et al.
N Engl J Med . 2024 Jun; 390(23):2156-2164. PMID: 38899694
Background: Variants in and (encoding apolipoprotein E and presenilin 1, respectively) alter the risk of Alzheimer's disease. We previously reported a delay of cognitive impairment in a person with autosomal...
6.
Diez I, Ortiz-Teran L, Ng T, Albers M, Marshall G, Orwig W, et al.
Nat Commun . 2024 Jun; 15(1):4809. PMID: 38844444
The direct access of olfactory afferents to memory-related cortical systems has inspired theories about the role of the olfactory pathways in the development of cortical neurodegeneration in Alzheimer's disease (AD)....
7.
Molina-Henry D, Raman R, Liu A, Langford O, Johnson K, Shum L, et al.
Alzheimers Dement . 2024 Apr; 20(6):3827-3838. PMID: 38629508
Introduction: In trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron...
8.
Aguero C, Dhaynaut M, Amaral A, Moon S, Neelamegam R, Scapellato M, et al.
Acta Neuropathol . 2024 Jan; 147(1):25. PMID: 38280071
We and others have shown that [F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to tau aggregates in Alzheimer's (AD) but has relatively low affinity...
9.
Su Y, Protas H, Luo J, Chen K, Alosco M, Adler C, et al.
Alzheimers Dement . 2023 Dec; 20(3):1827-1838. PMID: 38134231
Introduction: Tau is a key pathology in chronic traumatic encephalopathy (CTE). Here, we report our findings in tau positron emission tomography (PET) measurements from the DIAGNOSE CTE Research Project. Method:...
10.
Bonomi S, Lu R, Schindler S, Bui Q, Lah J, Wolk D, et al.
Ann Neurol . 2023 Dec; 95(3):495-506. PMID: 38038976
Objective: Biomarkers of Alzheimer disease vary between groups of self-identified Black and White individuals in some studies. This study examined whether the relationships between biomarkers or between biomarkers and cognitive...